<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28461310</PMID><DateCompleted><Year>2018</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1098-6596</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>7</Issue><PubDate><Year>2017</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Antimicrobial agents and chemotherapy</Title><ISOAbbreviation>Antimicrob Agents Chemother</ISOAbbreviation></Journal><ArticleTitle>Structure of the Enterovirus 71 3C Protease in Complex with NK-1.8k and Indications for the Development of Antienterovirus Protease Inhibitor.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e00298-17</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.00298-17</ELocationID><Abstract><AbstractText>Hand-foot-and-mouth disease (HFMD), caused by enterovirus, is a threat to public health worldwide. To date, enterovirus 71 (EV71) has been one of the major causative agents of HFMD in the Pacific-Asia region, and outbreaks with EV71 cause millions of infections. However, no drug is currently available for clinical therapeutics. In our previous works, we developed a set of protease inhibitors (PIs) targeting the EV71 3C protease (3C<sup>pro</sup>). Among these are NK-1.8k and NK-1.9k, which have various active groups and high potencies and selectivities. In the study described here, we determined the structures of the PI NK-1.8k in complex with wild-type (WT) and drug-resistant EV71 3C<sup>pro</sup> Comparison of these structures with the structure of unliganded EV71 3C<sup>pro</sup> and its complex with AG7088 indicated that the mutation of N69 to a serine residue destabilized the S2 pocket. Thus, the mutation influenced the cleavage activity of EV71 3C<sup>pro</sup> and the inhibitory activity of NK-1.8k in an <i>in vitro</i> protease assay and highlighted that site 69 is an additional key site for PI design. More information for the optimization of the P1' to P4 groups of PIs was also obtained from these structures. Together with the results of our previous works, these in-depth results elucidate the inhibitory mechanism of PIs and shed light to develop PIs for the clinical treatment of infections caused by EV71 and other enteroviruses.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 American Society for Microbiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yaxin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Pharmacy &amp; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>College of Pharmacy &amp; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhai</LastName><ForeName>Yangyang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Pharmacy &amp; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>College of Pharmacy &amp; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yuna</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Science, Beijing, China sunyn@moon.ibp.ac.cn shanglq@nankai.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Luqing</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>College of Pharmacy &amp; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China sunyn@moon.ibp.ac.cn shanglq@nankai.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Antimicrob Agents Chemother</MedlineTA><NlmUniqueID>0315061</NlmUniqueID><ISSNLinking>0066-4804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007555">Isoxazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011760">Pyrrolidinones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>47E5O17Y3R</RegistryNumber><NameOfSubstance UI="D010649">Phenylalanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.28</RegistryNumber><NameOfSubstance UI="D000086042">3C Viral Proteases</NameOfSubstance></Chemical><Chemical><RegistryNumber>HG18B9YRS7</RegistryNumber><NameOfSubstance UI="D014633">Valine</NameOfSubstance></Chemical><Chemical><RegistryNumber>RGE5K1Q5QW</RegistryNumber><NameOfSubstance UI="C118874">rupintrivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086042" MajorTopicYN="N">3C Viral Proteases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007555" MajorTopicYN="N">Isoxazoles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010649" MajorTopicYN="N">Phenylalanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011760" MajorTopicYN="N">Pyrrolidinones</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014633" MajorTopicYN="N">Valine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EV71</Keyword><Keyword MajorTopicYN="N">crystal structure</Keyword><Keyword MajorTopicYN="N">inhibitor</Keyword><Keyword MajorTopicYN="N">mechanism</Keyword><Keyword MajorTopicYN="N">protease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>12</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28461310</ArticleId><ArticleId IdType="pmc">PMC5487676</ArticleId><ArticleId IdType="doi">10.1128/AAC.00298-17</ArticleId><ArticleId IdType="pii">AAC.00298-17</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chan KP, Goh KT, Chong CY, Teo ES, Lau G, Ling AE. 2003. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis 9:78&#x2013;85. doi:10.3201/eid1301.020112.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1301.020112</ArticleId><ArticleId IdType="pmc">PMC2873753</ArticleId><ArticleId IdType="pubmed">12533285</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen KT, Chang HL, Wang ST, Cheng YT, Yang JY. 2007. Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998-2005. Pediatrics 120:e244&#x2013;e252. doi:10.1542/peds.2006-3331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2006-3331</ArticleId><ArticleId IdType="pubmed">17671037</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Qing J, Sun Y, Rao Z. 2014. Suramin inhibits EV71 infection. Antiviral Res 103:1&#x2013;6. doi:10.1016/j.antiviral.2013.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.12.008</ArticleId><ArticleId IdType="pubmed">24374150</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Perera R, Cardosa J, Kuhn RJ, Rossmann MG. 2012. Crystal structure of human enterovirus 71. Science 336:1274. doi:10.1126/science.1218713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1218713</ArticleId><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Wang Y, Shan C, Sun Y, Xu P, Zhou H, Yang C, Shi PY, Rao Z, Zhang B, Lou Z. 2013. Crystal structure of enterovirus 71 RNA-dependent RNA polymerase complexed with its protein primer VPg: implication for a trans mechanism of VPg uridylylation. J Virol 87:5755&#x2013;5768. doi:10.1128/JVI.02733-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02733-12</ArticleId><ArticleId IdType="pmc">PMC3648134</ArticleId><ArticleId IdType="pubmed">23487447</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Wang Y, Shan C, Chen C, Xu P, Song M, Zhou H, Yang C, Xu W, Shi PY, Zhang B, Lou Z. 2012. Enterovirus 71 VPg uridylation uses a two-molecular mechanism of 3D polymerase. J Virol 86:13662&#x2013;13671. doi:10.1128/JVI.01712-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01712-12</ArticleId><ArticleId IdType="pmc">PMC3503026</ArticleId><ArticleId IdType="pubmed">23055549</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu YC, Hsu JT, Huang JH, Ho MS, Ho YC. 2003. Formation of enterovirus-like particle aggregates by recombinant baculoviruses co-expressing P1 and 3CD in insect cells. Biotechnol Lett 25:919&#x2013;925. doi:10.1023/A:1024071514438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1024071514438</ArticleId><ArticleId IdType="pubmed">12889824</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui S, Wang J, Fan T, Qin B, Guo L, Lei X, Wang J, Wang M, Jin Q. 2011. Crystal structure of human enterovirus 71 3C protease. J Mol Biol 408:449&#x2013;461. doi:10.1016/j.jmb.2011.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2011.03.007</ArticleId><ArticleId IdType="pmc">PMC7094522</ArticleId><ArticleId IdType="pubmed">21396941</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto HH, Schirmeister T. 1997. Cysteine proteases and their inhibitors. Chem Rev 97:133&#x2013;172. doi:10.1021/cr950025u.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cr950025u</ArticleId><ArticleId IdType="pubmed">11848867</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung-Toung R, Zhao Y, Li W, Tam TF, Karimian K, Spino M. 2006. Thiol proteases: inhibitors and potential therapeutic targets. Curr Med Chem 13:547&#x2013;581. doi:10.2174/092986706776055733.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/092986706776055733</ArticleId><ArticleId IdType="pubmed">16515521</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah F, Mukherjee P, Gut J, Legac J, Rosenthal PJ, Tekwani BL, Avery MA. 2011. Identification of novel malarial cysteine protease inhibitors using structure-based virtual screening of a focused cysteine protease inhibitor library. J Chem Infect Model 51:852&#x2013;864. doi:10.1021/ci200029y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ci200029y</ArticleId><ArticleId IdType="pubmed">21428453</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L, Zhu S, Wang Y, Lou Z, Sun Y. 2015. A comprehensive procedure for antiviral inhibitor discovery using EV71 as an example. Biophys Rep 1:81&#x2013;89. doi:10.1007/s41048-015-0006-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s41048-015-0006-z</ArticleId><ArticleId IdType="pmc">PMC4762143</ArticleId><ArticleId IdType="pubmed">26942222</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang L, Zhang S, Yang X, Sun J, Li L, Cui Z, He Q, Guo Y, Sun Y, Yin Z. 2015. Biochemical characterization of recombinant enterovirus 71 3C protease with fluorogenic model peptide substrates and development of a biochemical assay. Antimicrob Agents Chemother 59:1827&#x2013;1836. doi:10.1128/AAC.04698-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.04698-14</ArticleId><ArticleId IdType="pmc">PMC4356770</ArticleId><ArticleId IdType="pubmed">25421478</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Wang Y, Cao L, Wang P, Qing J, Zheng Q, Shang L, Yin Z, Sun Y. 2016. A conserved inhibitory mechanism of a lycorine derivative against enterovirus and hepatitis C virus. Antimicrob Agents Chemother 60:913&#x2013;924. doi:10.1128/AAC.02274-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.02274-15</ArticleId><ArticleId IdType="pmc">PMC4750679</ArticleId><ArticleId IdType="pubmed">26596952</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang L, Wang Y, Qing J, Shu B, Cao L, Lou Z, Gong P, Sun Y, Yin Z. 2014. An adenosine nucleoside analogue NITD008 inhibits EV71 proliferation. Antiviral Res 112:47&#x2013;58. doi:10.1016/j.antiviral.2014.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2014.10.009</ArticleId><ArticleId IdType="pubmed">25446894</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Yang B, Zhai Y, Yin Z, Sun Y, Rao Z. 2015. Peptidyl aldehyde NK-1.8k suppresses enterovirus 71 and enterovirus 68 infection by targeting protease 3C. Antimicrob Agents Chemother 59:2636&#x2013;2646. doi:10.1128/AAC.00049-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00049-15</ArticleId><ArticleId IdType="pmc">PMC4394787</ArticleId><ArticleId IdType="pubmed">25691647</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai Y, Ma Y, Ma F, Nie Q, Ren X, Wang Y, Shang L, Yin Z. 2016. Structure-activity relationship study of peptidomimetic aldehydes as enterovirus 71 3C protease inhibitors. Eur J Med Chem 124:559&#x2013;573. doi:10.1016/j.ejmech.2016.08.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2016.08.064</ArticleId><ArticleId IdType="pubmed">27614190</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai Y, Zhao X, Cui Z, Wang M, Wang Y, Li L, Sun Q, Yang X, Zeng D, Liu Y, Sun Y, Lou Z, Shang L, Yin Z. 2015. Cyanohydrin as an anchoring group for potent and selective inhibitors of enterovirus 71 3C protease. J Med Chem 58:9414&#x2013;9420. doi:10.1021/acs.jmedchem.5b01013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.5b01013</ArticleId><ArticleId IdType="pubmed">26571192</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo CJ, Shie JJ, Fang JM, Yen GR, Hsu JT, Liu HG, Tseng SN, Chang SC, Lee CY, Shih SR, Liang PH. 2008. Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents. Bioorg Med Chem 16:7388&#x2013;7398. doi:10.1016/j.bmc.2008.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2008.06.015</ArticleId><ArticleId IdType="pmc">PMC7125518</ArticleId><ArticleId IdType="pubmed">18583140</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LS, Hendrickson TF, Love RA, Prins TJ, Marakovits JT, Zhou R, Tikhe J, Ford CE, Meador JW, Ferre RA, Brown EL, Binford SL, Brothers MA, DeLisle DM, Worland ST. 1999. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc Natl Acad Sci U S A 96:11000&#x2013;11007. doi:10.1073/pnas.96.20.11000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.20.11000</ArticleId><ArticleId IdType="pmc">PMC34232</ArticleId><ArticleId IdType="pubmed">10500114</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick AK, Binford SL, Brothers MA, Jackson RL, Ford CE, Diem MD, Maldonado F, Dragovich PS, Zhou R, Prins TJ, Fuhrman SA, Meador JW, Zalman LS, Matthews DA, Worland ST. 1999. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 43:2444&#x2013;2450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC89498</ArticleId><ArticleId IdType="pubmed">10508022</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Fan T, Yao X, Wu Z, Guo L, Lei X, Wang M, Jin Q, Cui S. 2011. Crystal structures of enterovirus 71 3C protease complexed with rupintrivir reveal the roles of catalytically important residues. J Virol 85:10021&#x2013;10030. doi:10.1128/JVI.05107-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.05107-11</ArticleId><ArticleId IdType="pmc">PMC3196404</ArticleId><ArticleId IdType="pubmed">21813612</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu G, Qi J, Chen Z, Xu X, Gao F, Lin D, Qian W, Liu H, Jiang H, Yan J, Gao GF. 2011. Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J Virol 85:10319&#x2013;10331. doi:10.1128/JVI.00787-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00787-11</ArticleId><ArticleId IdType="pmc">PMC3196414</ArticleId><ArticleId IdType="pubmed">21795339</ArticleId></ArticleIdList></Reference><Reference><Citation>Otwinowski Z, Minor W. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307&#x2013;326. doi:10.1016/S0076-6879(97)76066-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0076-6879(97)76066-X</ArticleId><ArticleId IdType="pubmed">27754618</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. 2007. Phaser crystallographic software. J Appl Crystallogr 40:658&#x2013;674. doi:10.1107/S0021889807021206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0021889807021206</ArticleId><ArticleId IdType="pmc">PMC2483472</ArticleId><ArticleId IdType="pubmed">19461840</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Cowtan K. 2004. COOT: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126&#x2013;2132. doi:10.1107/S0907444904019158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444904019158</ArticleId><ArticleId IdType="pubmed">15572765</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, Read RJ, Sacchettini JC, Sauter NK, Terwilliger TC. 2002. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 58:1948&#x2013;1954. doi:10.1107/S0907444902016657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444902016657</ArticleId><ArticleId IdType="pubmed">12393927</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen VB, Arendall WB III, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC. 2010. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66:12&#x2013;21. doi:10.1107/S0907444909042073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444909042073</ArticleId><ArticleId IdType="pmc">PMC2803126</ArticleId><ArticleId IdType="pubmed">20057044</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLano W. 2002. The PyMOL molecular graphics system. DeLano Scientific, San Carlos, CA.</Citation></Reference><Reference><Citation>Zeng D, Ma Y, Zhang R, Nie Q, Cui Z, Wang Y, Shang L, Yin Z. 2016. Synthesis and structure-activity relationship of &#x3b1;-keto amides as enterovirus 71 3C protease inhibitors. Bioorg Med Chem Lett 26:1762&#x2013;1766. doi:10.1016/j.bmcl.2016.02.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2016.02.039</ArticleId><ArticleId IdType="pubmed">26916437</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>